In this white paper, you will learn how clinical trial simulation (CTS) can support early market access planning by predicting a range of feasible trial results of a new treatment that can be fed into an economic model, making it possible to anticipate challenges to the econ … Read More »

Specialty medications, which have emerged as important new treatment options for complex diseases like oncology, rheumatology and neurology, now represent approximately 50% of the overall pharmaceutical market spend, according to the report, Medicine Use and Spending in the … Read More »

PRA has recently released a white paper about technology’s effects on rare disease research. Approximately 7,000 rare diseases affect an estimated 350 million people worldwide, and with diagnostic advances, new diseases are discovered every day. Although the number of clinic … Read More »

PRA has written a new white paper on the considerations for planning and conducting global rare disease clinical trials. Rare disease trials are inherently designed to include fewer patients, are often longer in duration, and more frequently terminated than trials in more co … Read More »

Comparative clinical benefit assessments are at the core of Health Technology Assessments (HTAs) in Europe. HTAs are a multi-disciplinary process considering input and evidence from medical, social, and economic sources. They are used to inform the design of health policies … Read More »

Finding a home for your biopharmaceutical company’s new orphan drug doesn’t just happen after it is FDA approved. The successful commercialization of your promising new drug requires a focused and well-planned distribution model. But first, some background. Orphan drugs trea … Read More »

PRA has written a new white paper on conducting clinical trials with adolescents, specifically children with impaired mental capacity. In the majority of clinical trials we undertake, the consent process is fairly straightforward; however, we do conduct studies in patients w … Read More »

By Jim Datin, President and CEO, BioAgilytix Bioanalytical outsourcing has changed dramatically in the past 30 years, which isn’t surprising when you consider how our economy, the healthcare market, technology, and drugs themselves have changed in that same period. In order … Read More »

October 15-16, 2018 in Washington, D.C. During the 2018 NORD Rare Summit, over 700 leaders from FDA, NIH, industry, patient groups, payers and research institutions will address the New Era of Patient-Focused Innovation. Together, NORD Rare Summit attendees will explore the … Read More »

At the 2018 DIA conference in Boston, Taren Grom, Editor-in-Chief of PharmaVOICE sat down with Peter Benton to discuss the evolution of clinical research and CROs. Some of the topics covered include… The evolution of the CRO industry The sustainability of the current M … Read More »

by Carlos Rodarte, Founder & Managing Director, Volar Health, LLC This is part three of a three-part series that discusses how enhanced access to in-depth health data is impacting our understanding of personhood, the environment around us, and the pharma model. Focusing … Read More »

In this blog post, we’ll share some highlights about Bhaskar Sambasivan, and see some of the reasons why he was honored in this year’s PharmaVOICE 100. You can also read his full profile here. He is leading the convergence of life sciences and healthcare. He has made investm … Read More »

In this blog post, we’ll share some highlights about Rami Levin, and see some of the reasons why he was honored in this year’s PharmaVOICE 100. You can also read his full profile here. Since being named president of Sobi North America in 2014, Rami Levin has built the compan … Read More »

Medidata NEXT is an immersive experience that unites 3,000 professionals in Life Sciences across seven global events. At NEXT, you’ll have the opportunity to connect with, learn from and be inspired by an array of industry thought leaders and so much more. Come see what the … Read More »

By Jim Datin, President and CEO, BioAgilytix Finding the right talent is challenging for any organization in any industry, but when you operate in a technical field that requires highly skilled workers, it can be even more difficult. Back in the late 90s during the peak of t … Read More »

Are we closer to finding a cure for MS? Attend this webinar to find out. July 11, 2018 | 10:00am ET Discover insights from the experts at GeNeuro, a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, about the first clini … Read More »

By Jim Datin, President and CEO of BioAgilytix There are a number of factors driving rapid growth of the global biologics market today. For one, pharmaceutical and biotech companies are shifting more investment into the discovery and development of large molecule therapeutic … Read More »

by Carlos Rodarte, Founder & Managing Director, Volar Health, LLC This is part two of a three-part series that discusses how enhanced access to in-depth health data is impacting our understanding of personhood, the environment around us, and the pharma model. Our Environ … Read More »

by Carlos Rodarte, Founder & Managing Director, Volar Health, LLC This is part one of a three-part series that will discuss how enhanced access to in-depth health data is impacting our understanding of personhood, the environment around us, and the pharma model. A New Un … Read More »

What do you get when Senior Pharmaceutical Executives get together and brainstorm about disruptive innovation in the Life Sciences industry? You get some pretty interesting perspectives, and perhaps even a glimpse into the future. Early in 2018, ICON gathered a group of indu … Read More »